**About NIZHPHARM**

**Nizhny Novgorod Chemical and Pharmaceutical Plant, shortly as Nizhpharm**, is a production site of STADA international pharmaceutical group.

STADA has more than 125-year history and acts in accordance with its purpose "Caring for people’s health as a trusted partner".

STADA focuses on the internationalization of its production and business, while remaining a local market player in each region. Today, STADA has one of the deepest **levels of localization – more than 65%,** and continues investing in this direction.

STADA Group includes more than 20 production facilities worldwide, including the Russian site Nizhpharm (Nizhny Novgorod).

Production site **Nizhpharm became a part of STADA in 2004**. It is the largest Russian manufacturer of semi-solid dosage forms (ointments, gels, creams) and suppositories. The production site with a century-old history was the first Russian enterprise that confirmed its compliance with international GMP quality standards.

The total **area of the facility is 45.9 k sq.m**. The area of the production zone is 14.7 k sq.m and includes 2.6 k sq.m. – the area of clean production zones of class D and C, workshops for ointments, creams, gels, liniments (semi-solid dosage forms), suppositories, tablets, medical products, liquid dosage forms. The annual production capacities of NIZHPHARM amount to **2.377 mio kg (2377 tons) of semi-solid dosage forms, 474 mio suppositories, 85 mio tablets, 8.5 mio packs of medical devices, 0,6 mio liquid dosage forms.**

Since 2004, Nizhpharm has implemented one of the best quality management systems among Russian pharmaceutical manufacturers.

Nizhpharm was one of the first pharmaceutical production facilities in Russia to receive certificates from the Ministry of Health of the Russian Federation and the World Health Organization on the compliance of the company's quality assurance system with Russian and international GMP standards.

Today, Nizhpharm **supplies its products to 15 foreign countries** with more than 240 exported SKUs.

Due to the high quality standards, STADA's production site Nizhpharm is gradually **becoming a center of excellence for the production of semi-solid dosage forms and suppositories in STADA group** - an enterprise to which foreign technologies are transferred from STADA production sites in Serbia and the UK.

The medicinal products transferred from Serbia will be manufactured at Nizhpharm site in more **than 2.5 million** **suppositories** per year and will be delivered mainly to the Russia, Balkans and CIS countries. The medicinal products transferred from the UK will be produced in almost **3.85 million** **suppositories** per year and will be delivered to 7 countries, including the UK, United Arab Emirates, and Yemen.

In the next three years, STADA plans to invest about 10 million euros in a localization project on the territory of the Nizhpharm site to transfer the production of a number of medicines from its foreign production sites to Russia.

The company's efforts to increase export volumes have been awarded in numerous competitions and contests. Thus, according to the results of the last five years, NIZHPHARM is recognized as the best exporter of the Russian pharmaceutical industry in the regional competition of the Ministry of Industry and Trade of the Russian Federation.

In 2015, Nizhpharm was included by the Ministry of Industry and Trade of Russia in the List of Companies with a significant impact on the development of industries and trade.

At the moment, Nizhpharm employs **more than 1000 people** and manufactures such STADA products as: **Vitaprost, Levomekol, Aqualor, Lavomax, Natalsid, Hexicon, Depantol Chondroxide, Mataren PLUS,** etc.